Valvular & structural heart disease
Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial
Study context
- Population
- Patients with severe and symptomatic aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI)
- Planned comparison
- comparing the effect of empagliflozin to placebo
- Primary endpoint
- difference in left ventricular (LV) mass indexed to body surface area (measured by cardiac CT)
- Follow-up
- From pre-AVR to 6 months post-AVR
Methodological details1:1 ratio, 180 days of treatment
- 1:1 ratio
- 180 days of treatment
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial. Am Heart J. Published 27 March 2026. doi:10.
Summarised from the published abstract; every number is checked against it